Patients annually who could benefit from ALDH1A3-targeted therapies
1
M+
Cancer patients with tumors expressing high ALDH1A3 levels
2
%
Theranib Inc. develops ALDH1A3-focused therapies, advancing personalized medicine by integrating biomarker-driven precision diagnostics to deliver tailored treatments for patients with elevated ALDH1A3 levels. By leveraging cutting-edge research and preclinical models, these therapies ensure accurate targeting of tumor cells without affecting healthy tissue. This approach not only enhances the effectiveness of cancer treatment but also reduces the overall burden on patients undergoing therapy, leading to improved survival rates and quality of life
Theranib’s groundbreaking compound, VE3, is a first-in-class ALDH1A3 inhibitor specifically designed to:
VE3 has demonstrated high specificity in preclinical models, effectively targeting tumors with elevated ALDH1A3 levels without impacting healthy cells. Pharmacokinetic studies reveal excellent bioavailability, making it suitable for once-daily dosing with minimal side effects.
The Expanding Role of ALDH1A3 in Cancer
Discover the expanding role of ALDH1A3 in cancer stem cells and its th
ALDH1A3 and Breast Cancer Progression
Explore the pivotal role of ALDH1A3 in breast cancer progression highl
Theranib’s US Patent Published
Theranib Inc. announces the publication of its US patent on January 9,
